Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYMD-1 in Sarcopenia/Frailty
NCT05283486Phase 2Completed
- Sponsor
- TNF Pharmaceuticals, Inc.
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isomyosamine in Sarcopenia, frailty syndrome, sponsored by TNF Pharmaceuticals, Inc.. Started Feb 2022; status: completed.
02
Drugs
isomyosamine
03
Conditions
Sarcopeniafrailty syndrome
Beyond the preview
Go deeper on NCT05283486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283486.